Who
Margaret A. Alexander
President and CEO
Company insider
Files Form 4 as: President and CEO, Ovid Therapeutics.
In numbers
- Trades disclosed
- 11
- Buys
- 1
- Sells
- 2
- Bought
- $4,971
- Sold
- $37K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 9 Sep 2024
- Last trade
- 26 Feb 2026
- Last filed
- 2 Mar 2026
Companies traded
Activity over time
1 Jan 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Feb 2026filed 2 Mar 2026 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,435,000 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,435,000 at $0.00 | filing |
| 23 Feb 2026filed 2 Mar 2026 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Sold | $17K11,656 at $1.45 | filing |
| 23 Feb 2026filed 2 Mar 2026 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Sold | $17K11,656 at $1.45 | filing |
| 4 Jan 2026filed 5 Jan 2026 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —890,000 at $0.00 | filing |
| 4 Jan 2026filed 5 Jan 2026 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —890,000 at $0.00 | filing |
| 26 Feb 2025filed 28 Feb 2025 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,9565,279 at $0.56 | filing |
| 20 Feb 2025filed 24 Feb 2025 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —262,500 at $0.00 | filing |
| 20 Feb 2025filed 24 Feb 2025 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Code A | —43,750 at $0.00 | filing |
| 27 Jan 2025filed 29 Jan 2025 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Bought | $4,9716,810 at $0.73 | filing |
| 9 Sep 2024filed 11 Sep 2024 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
News
Ovid Therapeutics (NASDAQ:OVID) and Perrigo (NYSE:PRGO) Head to Head ReviewOVID · themarketsdaily.com · 20 Oct 2026Ovid Therapeutics (NASDAQ:OVID) Stock Rated "Overweight" in New Coverage at Cantor FitzgeraldOVID · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name Margaret A. Alexander; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.